Nanovision Biosciences Inc San Diego, CA - 92122

Nanovision Biosciences Inc is categorized under Commercial Medical Research in San Diego, CA and active since 2013.

Nanovision Biosciences Inc was established in 2013, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.

If you are seeking more information, feel free to contact Robert Murrill at the company’s single location by writing to 9171 Towne Center Drive # 250, San Diego, California CA 92122 or by phoning (858) 455-5400. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Nanovision Biosciences Inc
Contact Person: Robert Murrill
Address: 9171 Towne Center Drive # 250, San Diego, California 92122
Phone Number: (858) 455-5400
Annual Revenue (USD): $50.000 to $99.999
Founded: 2013
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Medical Research
SIC Code: 8731
NAICS Code: 541712
Share This Business:

Nanovision Biosciences Inc was started in 2013 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.

Feel free to contact Robert Murrill for inquiries that concern Nanovision Biosciences Inc by calling the company number (858) 455-5400, as your correspondence is most welcome. Additionally, the physical location of the single location of Nanovision Biosciences Inc can be found at the coordinates 32.873382,-117.207163 as well as the street address 9171 Towne Center Drive # 250 in San Diego, California 92122.

For its online presence, you may visit Nanovision Biosciences Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.